Skip to main content

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease


Alzheimer’s disease (AD) is the most common cause of dementia among older adults. Accumulation of amyloid-β (Aβ) in the brain is considered central in AD pathogenesis and its understanding crucial for developing new diagnostic and therapeutic approaches. Recent literature suggests that ageing may induce post translational modifications in Aβ, in the form of spontaneous amino acid modifications, which enhance its pathogenic properties, contributing to its aggregation.

In this study, we have investigated whether the isoaspartate (IsoD-Aβ) and pyroglutamate (pE3-Aβ) modified forms of Aβ are significantly associated with AD pathology or represent markers of ageing. Cerebral neocortex of 27 AD cases, 32 old controls (OC) and 11 young controls (YC) was immunostained for pE3-Aβ and IsoD-Aβ, quantified as protein load and correlated with other Aβ forms and p-TAU. IsoD-Aβ and pE3-Aβ were detected at low levels in non-demented controls, and significantly increased in AD (p ≤ 0.001), with a characteristic deposition of IsoD-Aβ in blood vessel walls and pE3-Aβ within neurons. Both AD and OC showed positive associations between IsoD-Aβ and Aβ (p = 0.003 in AD and p = 0.001 in OC) and between IsoD-Aβ and pE3-Aβ (p = 0.001 in AD and OC). This last association was the only significant pE3-Aβ correlation identified in AD, whereas in the control cohorts pE3-Aβ also correlated with Aβ and AβPP (p = 0.001 in OC and p = 0.010 in YC).

Our analyses suggest that IsoD-Aβ accumulation starts with ageing; whereas pE3-Aβ deposition is more closely linked to AD. Our findings support the importance of age-related modifications of Aβ in AD pathogenesis.


Alzheimer’s disease (AD) is the most common cause of dementia in the elderly population. The molecular pathogenesis of this disease is only partially understood and the comprehension of new key aspects of its neurobiology is crucial for the future development of early diagnostic approaches and effective treatments [34]. AD is characterized by the intra- [5, 39] and extracellular accumulation in the brain of aggregated amyloid-β (Aβ), and of hyperphosphorylated tau (p-TAU) within the neurons [32]. Aβ misfolding, resulting in its aggregation into oligomers, protofibrils and fibrils, is considered crucial in the development of AD [33] and synergistic with tau pathology [24]. Aβ is a family of peptides generated by β- and γ-secretase sequential cleavages of the amyloid precursor protein (APP) and currently regarded as one of the major therapeutic targets in AD [34].

Ageing is considered the main risk factor for AD, but the pathway through which ageing contributes to Aβ misfolding remains unclear. In particular, we still do not know whether ageing induces molecular changes in Aβ, driving its accumulation in the brain. Recent literature suggests that ageing may induce post-translational modifications, in particular spontaneous Aβ amino acid modifications, defined as age-related modifications, which enhance its pathogenic properties [9, 21, 23, 27, 44], leading to the “Protein ageing Hypothesis of AD” [23]. It is conceivable that accumulation of age-related amino acid modifications could start early in the ageing process [21]. Consequently, the understanding of the relationship between age-related-modifications of Aβ and AD pathology could potentially identify new diagnostic and therapeutic approaches in early AD.

Prominent examples of these age-modified forms of Aβ include isomerization (isoD-Aβ) and racemization of aspartate residues, and pyroglutamate formation at the N-terminal of Aβ (pE-Aβ) [14]. IsoD-Aβ, similarly to the racemized form of aspartate, is the result of a chemically spontaneous and non-enzymatic reaction that introduces an additional methylene group in the peptide backbone of Aβ [37]. The formation of pE-Aβ is the consequence of a truncation at the level of a N-terminal glutamate, followed by the dehydration catalyzed by Glutaminyl Cyclase to form the cyclic pyroglutamate [11]. Evidence supports a direct role of these modifications in altering the intrinsic properties of Aβ, as to accelerate its deposition, or to impair its clearance and degradation [23, 37]. In vitro studies have shown that IsoD-Aβ was associated with accelerated Aβ aggregation and fibril formation [23, 36]; and known mutations, where aspartic acid of Aβ is replaced by asparagine and then modified into isoD, are associated with early-onset AD and high levels of Aβ deposition [3, 6, 42]. Similar observations were reported for pE-Aβ, in particular with the modification at the glutamate in position 3 of Aβ (pE3-Aβ). It is toxic in primary culture of neurons and astrocytes [28], and its expression in mouse and Drosophila brains acts as an important source of toxicity, displaying an accelerated aggregation, enhanced synaptic toxicity, high stability and resistance to degradation [19, 28, 31, 38]. Moreover, it was demonstrated that small amounts of pE-Aβ oligomers are sufficient to trigger the aggregation of unmodified Aβ1–42, leading to the formation of hypertoxic Aβ1–42 oligomers [22]. Of note, passive immunization with a pE-Aβ monoclonal antibody in APPswe/PS1ΔE9 AD mouse model, was able to lower Aβ plaque burden and prevent cognitive impairment [4]. Therefore, the formation of pE- and IsoD-Aβ may have a role in the pathological process of Aβ aggregation and accumulation.

In this study, we have addressed the question whether these Aβ modifications are significantly associated with AD pathology or if they represent physiological markers of ageing, using post-mortem brain tissue from AD cases compared to non-neuropathological old and young controls.

Materials and methods

Case selection

Seventy post-mortem cases were investigated divided among 3 cohorts as follows: 27 AD cases, 11 young controls defined as with no significant neuropathological abnormality (YC, <63 years old) and 32 old control cases with no significant neuropathological abnormality (OC, ≥ 63 years old), age-matched with the AD cohort. A summary of the cohorts is presented in Table 1 with additional information available in Additional file 1: Table S1. All AD cases had a clinical diagnosis of probable Alzheimer’s disease according to NINCDS–ADRDA criteria and cases with concomitant pathology were excluded. Diagnosis was made during life by an experienced clinician and post-mortem neuropathological consensus criteria for AD were satisfied, including Braak stage, by an experienced neuropathologist.

Table 1 Summary of the AD, old and young cohorts


Four μm formalin-fixed paraffin-embedded sections from the inferior parietal lobule (Brodmann area 40) were retrieved from the Brain banks for all cases. Protocols for tissue fixation and processing were similar in both brain banks. In addition, the staining was performed in batches with each batch including cases from all 3 cohorts to ensure compatibility of the staining. The following primary mouse monoclonal antibodies were used: 22C8 against 1–12 Aβ with 1,7 IsoAspartate modification (IsoD-Aβ) provided by Elan Pharmaceuticals Inc., US [29, 30]; 337.48 specific to Aβ with pyroglutamate at the third glutamate position (pE3-Aβ, BioLegend, US); 4G8, specific for the amino acid residues 17–24 of Aβ, which reacts to the abnormally processed isoforms, as well as precursor forms (AβPP) [1, 2, 12](BioLegend, US); 82E1, an Aβ N-terminal specific antibody, which does not cross react with non-β secretase cleaved APP (IBL, Japan, [8]); AT8, directed against the human tau, phosphorylated at Ser202 and Thr205 (p-TAU) (ThermoFisher Scientific, US) (Fig. 1 and Table 2).

Fig. 1
figure 1

Regions of APP recognized by the antibodies used in this study. Top of the figure: Illustration of APP. Aβ region is labelled in yellow and β and γ-secretase cleavage sites are indicated in red. Bottom of the figure: Illustration of the Aβ and APP regions recognized by 22C8, 337.48, 82E1, 4G8 clones. The positions of IsoD- and pE3-Aβ modifications recognized, respectively by clones 22C8 and 337.48, are indicated with triangles

Table 2 Antibodies and immunohistochemistry conditions

Immunohistochemistry was performed using the appropriate antigen retrieval method (Table 2). Biotinylated secondary antibody (rabbit anti-mouse) was from Dako (Denmark), and normal serum and avidin–biotin complex from Vector Laboratories (UK). Bound antibody was visualized using the avidin–biotin–peroxidase complex method (Vectastain Elite ABC) with 3,3′-diaminobenzidine as chromogen and 0.05% hydrogen peroxide as substrate (both from Vector Laboratories, UK). All sections were dehydrated before mounting in DePeX (VWR International, UK). Sections incubated in the absence of the primary antibody were included as negative controls.

IsoD-Aβ and pE3-Aβ quantification

Quantification was performed blind to the experimental group and identity of the cases. For each antibody and case, 30 images of cortical grey matter were taken using a ×20 objective lens, in a zigzag sequence in order to ensure that all cortical layers were represented in the quantification. The sampling pattern between all cases was consistent, starting at the depth of the sulcus and progressing up the sulcal wall to the gyral surface. The acquired images were analysed using ImageJ version 1.49 software (developed by Wayne Rasband NIH, US) with a threshold applied to the image to select and measure the total amount of specific immunostaining. The same threshold setting was maintained for all images of all cases stained for the same antibody, and the area fraction of the measure function provided the proportion (%) of the stained area related to the total area of the image (expressed as protein load).

Semi quantitative assessment

Immunodetection for Iso-DAβ and pE3-Aβ was assessed as present or absent according to the staining being defined as: intraneuronal deposits [5], dense-core plaques, diffuse plaques and vessel wall deposits (i.e. cerebral amyloid angiopathy: CAA) [35]. The staining was independently reviewed by two operators.

Statistical analysis

To compare the protein load of the different Aβ forms and p-TAU between the cohorts, the normality of each marker was assessed through examination of quantile-quantile plots (not shown). As the data were non-parametric, the Kruskal-Wallis test was performed for comparison among the three groups for each marker. To assess whether the presence of pE3-Aβ and IsoD-Aβ immunostaining in intraneuronal deposits, dense-core plaques, diffuse plaques and CAA differed significantly between AD and OC and OC and YC, the Fisher’s Exact Test was used.

To investigate the relationship of isoD-Aβ and pE3-Aβ with the other Aβ forms and p-TAU, correlations were performed using the Pearson or Spearman correlation coefficients, as determined by the normality of the markers. The threshold for statistical significance was set at 5% for intergroup comparisons and Fisher’s test and 1% for correlations, as determined by the use of SPSS 21.0 (IBM, US).


Quantification of IsoD and pE3-Aβ

The quantification of IsoD-Aβ, independently of the location of the staining, revealed that IsoD-Aβ load was significantly higher in AD compared to OC (p < 0.001) and AD vs YC (p = 0.001) cohorts. No significant difference was identified between OC and YC groups (Fig. 2a).

Fig. 2
figure 2

Quantification of IsoD-Aβ and pE3-Aβ loads. Both IsoD-Aβ (a) and pE3-Aβ (e) loads are significantly higher in the AD cases than in the OC and YC groups. Illustrations of immunostaining for IsoD-Aβ (b-d) and pE3-Aβ (f-h) in the 3 cohorts. Scale bar = 50 μm

Similarly, the pE3-Aβ load was significantly higher in AD vs OC (p = 0.001) and AD vs YC (p < 0.001) cases; while no significant difference was found between OC and YC groups (Fig. 2e).

IsoD-Aβ and pE3-Aβ immunodetection and locations

IsoD-Aβ and pE3-Aβ immunostaining was observed in the commonly identified Aβ locations in the brain: intraneuronal deposits, diffuse deposits, dense-core plaques, and CAA (Fig. 3a-d and f-i). However significant differences were observed between OC and AD regarding the presence of some of these neuropathological features (Fig. 3e-j).

Fig. 3
figure 3

Location of IsoD-Aβ and pE3-Aβ immunostaining. Illustrations of the different neuropathological features detected by immunostaining for IsoD-Aβ (upper panel) and pE3-Aβ (lower panel): intraneuronal (a, f*), diffuse deposits (b, g), core plaques (c, h), and cerebral amyloid angiopathy (CAA) (d, i). The assessment of the different neuropathological features shows that: (e) IsoD-Aβ in CAA, core plaques and neurons was significantly more frequent in AD vs OC; however intraneuronal IsoD-Aβ was limited to only 18% of AD cases; (j) pE3-Aβ was significantly more frequent in neurons, diffuse deposits and core plaques in AD compared to OC cases. Scale bar (a) = 50 μm; (b-i) = 25 μm

Overall, the comparison between AD and OC cases revealed that IsoD-Aβ immunostaining in core plaques and CAA was significantly more frequent in the AD vs OC cases (core plaques: AD = 96% vs OC = 44%, p < 0.0001; CAA: AD = 63% vs OC = 28%, p = 0.009) (Fig. 3e). IsoD-Aβ intraneuronal deposits were also significantly more present in AD than OC; however this feature was limited to only a minority of AD cases (AD = 18%; OC = 0%, p = 0.039). No significant difference was observed instead in relation to IsoD-Aβ stained diffuse deposits (p = 0.118) (Fig. 3e).

No IsoD-Aβ staining was identified in YC (Fig. 5j), with the exception of 2 cases among the oldest, who were 59 and 62 years old and had some diffuse and core plaques (Fig. 5l).

pE3-Aβ immunostaining was significantly more present in AD vs OC cases in intraneuronal deposits (AD = 52% vs OC = 9%, p < 0.001); in diffuse plaques (AD = 89% vs OC = 44%, p < 0.001); and core plaques (AD = 100% vs OC = 63%, p < 0.001) (Fig. 3j). No significant difference was observed instead in relation to pE3-Aβ CAA (p = 0.065).

pE3-Aβ was negative in the majority of YC (Fig. 5k). Only two YC cases, the same cases which have sparse isoD-Aβ deposits, also had sparse pE3-Aβ-positive immunostaining mainly as diffuse plaques, with the case aged 62 also having few core plaques (Fig. 5m).

Relationship between IsoD, pE3-Aβ and hallmarks of AD

Correlations were performed in the 3 cohorts between IsoD and pE3-Aβ loads each other, and respectively, with AβPP (clone 4G8), Aβ (clone 82E1), and p-TAU (AT8 antibody). All analyses are presented in Table 3 and Fig. 4 and the representative pictures in Fig. 5. In the AD group, two significant positive correlations were found for IsoD-Aβ with pE3-Aβ (ρ = 0.582, p = 0.001) and Aβ (ρ = 0.545, p = 0.003). In the OC cohort, significant positive associations were identified for IsoD-Aβ with pE3-Aβ (ρ = 0.557, p = 0.001), Aβ (ρ = 0.578, p = 0.001) and AβPP (ρ = 0.591, p < 0.001).

Table 3 Results of correlation analyses within the 3 cohorts
Fig. 4
figure 4

Correlation analysis. Representation of the most significant correlations (p < 0.01) observed in the AD, OC and YC cohorts

Fig. 5
figure 5

Pictures of IsoD-Aβ, pE-Aβ, Aβ, AβPP and p-TAU in AD, OC, and YC. Representative pictures of IsoD-Aβ (a), pE3-Aβ (b), Aβ (c), p-TAU (d) staining of AD cases, the significant correlations of which are described in Table 3. Representative pictures of IsoD-Aβ (e), pE3-Aβ (f), Aβ (g), AβPP (h) and p-TAU (i) staining of OC cases, the significant correlations of which are described in Table 3. IsoD-Aβ (j) and pE3-Aβ (k), as well as Aβ, AβPP and p-TAU staining were negative in the majority of YC. Only in two YC cases, IsoD-Aβ (l), pE3-Aβ (m), Aβ (n), AβPP (o) deposits were detectable. Scale bar = 50 μm

For pE3-Aβ in OC cohort, in addition to the correlation identified with IsoD-Aβ, there were positive significant associations with Aβ (ρ = 0.609, p < 0.001) and AβPP (ρ = 0.570, p = 0.001). Within the YC group, a positive correlation was observed between AβPP and pE3-Aβ load (ρ = 0.736, p = 0.010).


In this study, we have investigated two post-translational modifications of Aβ, IsoD-Aβ and pE3-Aβ, normally defined as age-related modifications [11, 21, 25], and explore whether their accumulation is significantly increased in AD patients compared with age-matched controls and younger controls. Our findings show that both IsoD-Aβ and pE3-Aβ can be detected at a low level in non-demented age-matched controls but both are at significantly higher levels in AD.

It is possible that these modified forms of Aβ start to form and aggregate years before other molecular lesions and symptoms of disease clearly appear. Indeed pE3-Aβ has been detected in the past not only in plaques but also in dispersible and soluble Aβ aggregates outside the plaques and described in pathologically preclinical AD cases [26]. Consequently in our study, some of non-demented age-matched controls might have actually died after IsoD-Aβ and pE3-Aβ accumulation in the brain had started, but before the formation of a significant Aβ burden.

The higher level of IsoD-Aβ in AD may be explained by the properties of the amino acid of Aβ. There is evidence that IsoD forms most easily at sequences in which the side chain of the C-flanking amino acid is relatively small and hydrophilic [36]. The most favourable C-flanking amino acids are Glycine (G), Serine (S), and Histidine (H). The Aβ sequence has S and G residues at the C-term of aspartate 7 (D7), rendering this residue most likely to be spontaneously transformed to IsoD with ageing. The other aspartate residue analysed, D1, is the first amino acid of the Aβ sequence, which is also the β-secretase site of APP. D1 does not have C-term residues favourable to spontaneous isomerization. However, its isomerization in AD can be driven by other chemical conditions, e.g. oxidative stress and production of radicals [18] as demonstrated for D-racemization [13, 40], occurring through the same chemical intermediate of D-isomerization [21]. Therefore, it is reasonable to hypothesize that in AD, IsoD-Aβ accumulates at a significantly higher level than during ageing due to faster isomerization of D7 or to a possible additional modification of D1; processes that are likely not to be mutually exclusive.

The increased pE3-Aβ in AD may be explained by increased expression of Glutaminyl cyclase (QC), the enzyme that catalyses the conversion of glutamate into pyroglutamate. QC was found in the cortex of AD patients [20] and its levels correlated with insoluble pE3-Aβ aggregates, and not with unmodified Aβ peptides. Noteworthy, in the same patients, the insoluble pE3-Aβ correlated with the cognitive decline better than elevated level of unmodified Aβ [20].

As expected, in our study, the majority of YC cases did not have IsoD- or pE3-Aβ forms. Of note, the only cases that had some immunostaining were among the oldest, aged 59 and 62 years, and thus close to the old control group.

Similar observations were reported in a study focused on brain tissues of cases with Down Syndrome (DS). Trisomy 21 is associated with the progressive development of AD neuropathology as observed in DS people in their forties. A study reported that deposits containing pE3-Aβ were not detectable in DS cases under 27 years old, while they were present in older cases [16].

Interestingly, our assessment of different features of Aβ deposits shows that the differences between AD and controls are not only quantitative, but also related to the specific compartments of brain parenchyma and vasculature where IsoD-Aβ and pE3-Aβ accumulate. IsoD-Aβ was largely extracellular, in core plaques as well as in blood vessel walls, in accordance with previous published data [14, 36]. While the majority of AD cases had both these features, they were less prevalent in the OC group. In AD, IsoD-Aβ in core plaques and CAA was more prevalent than IsoD-Aβ within neurons. This is in agreement with the results of a previous study focused on DS and small group of AD and OC with IsoD-Aβ detected in amyloid cores and vascular amyloid [10]. The limited intraneuronal detection of IsoD-Aβ is consistent with the location in the cytoplasm and endoplasmatic reticulum of L-isoaspartyl methyltransferase, the enzyme able to repair IsoD to L-aspartyl residue. This explains that possibilities to repair extracellular IsoD are very limited [36], implying that once extracellular IsoD-Aβ deposits are formed, differently from intraneuronal deposits, they might likely remain unrepaired.

We detected pE3-Aβ in the vasculature, as previously reported [17, 41], but in our larger cohorts the prevalence of this feature was not significantly greater in AD than controls. However, pE3-Aβ in AD was found in diffuse deposits, core plaques and intraneuronal deposits, in agreement with previous studies [17, 45] and in these specific locations, pE3-Aβ was significantly more frequent in AD than OC. Of note, pE3-Aβ in core plaques was the only feature observed in the majority of both AD and OC. A larger difference in the comparison of pE3-Aβ neuropathological features between OC and AD was related to intraneuronal pE3-Aβ, which was limited to few OC cases while present in 52% of AD. This suggests that intraneuronal accumulation of pE3-Aβ might be characteristic of AD, compatible with an increased somatic activity of QC enzyme. The presence of pE3-Aβ in plaques, might result instead from the possibility of secretion of this enzyme into the extracellular space, as observed in some experimental studies [7].

Our correlation analyses showed a number of relationships between IsoD and pE3-Aβ and hallmarks of AD. We observed positive associations of IsoD-Aβ with pE3-Aβ and Aβ (peptide with no N-terminal modifications) in AD. Of note, the same relationships were found in OC, although they had less IsoD-Aβ. This suggests that the presence of IsoD is associated with a process of accumulation of Aβ forms, already in progress with ageing. This is indeed in agreement with studies showing that isoaspartate post-translational modifications affect the fibrillization and toxicity properties of Aβ [3], possibly with a role in seeding the accumulation of Aβ species [43]. Interestingly in OC, both IsoD- and pE3-Aβ showed associations with AβPP and Aβ loads. In AD, despite the increased accumulation of IsoD-Aβ and pE3-Aβ, there was no association of the two modified forms with AβPP and only IsoD-Aβ correlated with Aβ load, while pE3-Aβ was independent from it. This may imply that different mechanisms control the accumulation of these Aβ modifications in ageing and in AD, with the existence of a direct link between IsoD-/pE3-Aβ accumulation and AβPP only during ageing.

p-TAU was associated with pE3-Aβ in both AD and OC cohorts, but not with the same strength as the other described associations. This relationship was already described in a study performed in 18 AD and 23 age-matched controls [17], where the data of both cohorts were combined. Accordingly, when we pooled AD and OC data, our association became stronger (ρ=0.6704, p < 0.0001) and similar to the previous published study, as shown in Additional file 1: Figure S1. Therefore, it is reasonable to hypothesize that the presence of pE3-Aβ in the brain leads to further neuropathological lesions, like the hyperphosphorylation of tau.

In summary, we have observed that high levels of IsoD- and pE3-Aβ are present in AD brain. IsoD-Aβ accumulation appears to be mainly related to ageing and, both in old and AD brains, this modification is associated with the build-up of unmodified Aβ as well as pE3-Aβ. In AD, IsoD-Aβ load is significantly higher than in OC and also accumulates significantly more in blood vessel walls. In contrast, pE3-Aβ appears to be more specifically linked to the disease process. In AD brain, pE3-Aβ deposition is significantly higher than in controls with a characteristic location in neurons. However, both post-translational modifications cannot be related at the moment to any temporal sequences of events.


These findings underline the importance of age-related post-translational modifications of Aβ in relation to AD. They complement the studies that have revealed the complexity of Aβ chemistry and activity [3, 15]. In addition, our observations support the relevance of investigating IsoD-Aβ and pE3-Aβ levels as potential biomarkers for AD and the impact of the different Aβ-targeted therapies on these modified forms of Aβ. This research could benefit in the future from the development and optimization of new analytical methods [46], able to separate with high resolution the different forms of Aβ peptides in biological fluids.



Alzheimer’s disease


the amyloid precursor protein




Precursor forms and Aβ


Cerebral amyloid angiopathy










Isoaspartate modified amyloid-beta


Old controls


Pyroglutamate modified amyloid-beta


Hyperphosphorylated tau


Glutaminyl cyclase




Young controls


  1. Aho L, Pikkarainen M, Hiltunen M, Leinonen V, Alafuzoff I (2010) Immunohistochemical visualization of amyloid-beta protein precursor and amyloid-beta in extra- and intracellular compartments in the human brain. J Alzheimers Dis 20:1015–1028.

    Article  CAS  PubMed  Google Scholar 

  2. Alafuzoff I, Pikkarainen M, Arzberger T, Thal DR, Al-Sarraj S, Bell J, Bodi I, Budka H, Capetillo-Zarate E, Ferrer I et al (2008) Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol 115:533–546.

    Article  CAS  PubMed  Google Scholar 

  3. Fossati S, Todd K, Sotolongo K, Ghiso J, Rostagno A (2013) Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid beta and the Asn23 Iowa mutation. Biochem J 456:347–360.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Frost JL, Liu B, Rahfeld JU, Kleinschmidt M, O'Nuallain B, Le KX, Lues I, Caldarone BJ, Schilling S, Demuth HU et al (2015) An anti-pyroglutamate-3 Abeta vaccine reduces plaques and improves cognition in APPswe/PS1DeltaE9 mice. Neurobiol Aging 36:3187–3199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H et al (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156:15–20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM (2001) Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 49:697–705

    Article  CAS  PubMed  Google Scholar 

  7. Hartlage-Rubsamen M, Morawski M, Waniek A, Jager C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HUet al (2011) Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathol 121: 705-719

  8. Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y (2004) Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun 319:733–737.

    Article  CAS  PubMed  Google Scholar 

  9. Inoue K, Hosaka D, Mochizuki N, Akatsu H, Tsutsumiuchi K, Hashizume Y, Matsukawa N, Yamamoto T, Toyo'oka T (2014) Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-beta in Alzheimer's brain tissues by covalent chiral derivatized ultraperformance liquid chromatography tandem mass spectrometry. Anal Chem 86:797–804.

    Article  CAS  PubMed  Google Scholar 

  10. Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ (1996) Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol 149:1823–1830

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Jawhar S, Wirths O, Bayer TA (2011) Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease. J Biol Chem 286:38825–38832.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kovacs GG, Lutz MI, Ricken G, Strobel T, Hoftberger R, Preusser M, Regelsberger G, Honigschnabl S, Reiner A, Fischer P et al (2016) Dura mater is a potential source of Abeta seeds. Acta Neuropathol 131:911–923.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kuge K, Kitamura K, Nakaoji K, Hamada K, Fujii N, Saito T, Fujii N (2010) Oxidative stress induces the formation of D-aspartyl residues in the elastin mimic peptides. Chem Biodivers 7:1408–1412.

    Article  CAS  PubMed  Google Scholar 

  14. Kummer MP, Heneka MT (2014) Truncated and modified amyloid-beta species. Alzheimers Res Ther 6:28.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lee J, Gillman AL, Jang H, Ramachandran S, Kagan BL, Nussinov R, Teran Arce F (2014) Role of the fast kinetics of pyroglutamate-modified amyloid-beta oligomers in membrane binding and membrane permeability. Biochemistry 53:4704–4714.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3:16–32.

    Article  CAS  PubMed  Google Scholar 

  17. Mandler M, Walker L, Santic R, Hanson P, Upadhaya AR, Colloby SJ, Morris CM, Thal DR, Thomas AJ, Schneeberger A et al (2014) Pyroglutamylated amyloid-beta is associated with hyperphosphorylated tau and severity of Alzheimer's disease. Acta Neuropathol 128:67–79.

    Article  CAS  PubMed  Google Scholar 

  18. McGrath LT, McGleenon BM, Brennan S, McColl D, Mc IS, Passmore AP (2001) Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 94:485–490

    Article  CAS  PubMed  Google Scholar 

  19. Meissner JN, Bouter Y, Bayer TA (2015) Neuron loss and behavioral deficits in the TBA42 mouse model expressing N-truncated Pyroglutamate Amyloid-beta3-42. J Alzheimers Dis 45:471–482.

    CAS  PubMed  Google Scholar 

  20. Morawski M, Schilling S, Kreuzberger M, Waniek A, Jager C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rubsamen M et al (2014) Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in Alzheimer's disease. J Alzheimers Dis 39:385–400.

    CAS  PubMed  Google Scholar 

  21. Moro ML, Collins MJ, Cappellini E (2010) Alzheimer's disease and amyloid beta-peptide deposition in the brain: a matter of 'aging'? Biochem Soc Trans 38:539–544.

    Article  CAS  PubMed  Google Scholar 

  22. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Ronicke R et al (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 485:651–655.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Orpiszewski J, Schormann N, Kluve-Beckerman B, Liepnieks JJ, Benson MD (2000) Protein aging hypothesis of Alzheimer disease. FASEB J 14:1255–1263

    CAS  PubMed  Google Scholar 

  24. Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, Beaudry T, Kang MS, Soucy JP, Labbe Aet al (2016) Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement

  25. Reissner KJ, Aswad DW (2003) Deamidation and isoaspartate formation in proteins: unwanted alterations or surreptitious signals? Cell Mol Life Sci 60:1281–1295.

    Article  CAS  PubMed  Google Scholar 

  26. Rijal Upadhaya A, Kosterin I, Kumar S, von Arnim CA, Yamaguchi H, Fandrich M, Walter J, Thal DR (2014) Biochemical stages of amyloid-beta peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. Brain 137:887–903.

    Article  PubMed  Google Scholar 

  27. Rosen RF, Tomidokoro Y, Farberg AS, Dooyema J, Ciliax B, Preuss TM, Neubert TA, Ghiso JA, LeVine H 3rd, Walker LC (2016) Comparative pathobiology of beta-amyloid and the unique susceptibility of humans to Alzheimer's disease. Neurobiol Aging 44:185–196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Russo C, Violani E, Salis S, Venezia V, Dolcini V, Damonte G, Benatti U, D'Arrigo C, Patrone E, Carlo P et al (2002) Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. J Neurochem 82:1480–1489

    Article  CAS  PubMed  Google Scholar 

  29. Schenk, D. B. B.. 2011. PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASES. United States patent application 20110177066 CA, US

    Google Scholar 

  30. Schenk, D. B.; Bard, F.; Yednock, T. 2004. HUMANIZED AND CHIMERIC N-TERMINAL AMYLOID BETA-ANTIBODIES. United States patent application 20046750324

    Google Scholar 

  31. Schlenzig D, Ronicke R, Cynis H, Ludwig HH, Scheel E, Reymann K, Saido T, Hause G, Schilling S, Demuth HU (2012) N-terminal pyroglutamate formation of Abeta38 and Abeta40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. J Neurochem 121:774–784.

    Article  CAS  PubMed  Google Scholar 

  32. Selkoe DJ (2011) Alzheimer's disease. Cold Spring Harb Perspect Biol 3.

  33. Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat Cell Biol 6:1054–1061.

    Article  CAS  PubMed  Google Scholar 

  34. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med 8:595–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189.

  36. Shimizu T, Matsuoka Y, Shirasawa T (2005) Biological significance of isoaspartate and its repair system. Biol Pharm Bull 28:1590–1596

    Article  CAS  PubMed  Google Scholar 

  37. Shimizu T, Watanabe A, Ogawara M, Mori H, Shirasawa T (2000) Isoaspartate formation and neurodegeneration in Alzheimer's disease. Arch Biochem Biophys 381:225–234.

    Article  CAS  PubMed  Google Scholar 

  38. Sofola-Adesakin O, Khericha M, Snoeren I, Tsuda L, Partridge L (2016) pGluAbeta increases accumulation of Abeta in vivo and exacerbates its toxicity. Acta Neuropathol Commun 4:109.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Takahashi RH, Nagao T, Gouras GK (2017) Plaque formation and the intraneuronal accumulation of beta-amyloid in Alzheimer's disease. Pathol Int 67:185–193.

    Article  CAS  PubMed  Google Scholar 

  40. Tambo K, Yamaguchi T, Kobayashi K, Terauchi E, Ichi I, Kojo S (2013) Racemization of the aspartic acid residue of amyloid-beta peptide by a radical reaction. Biosci Biotechnol Biochem 77:416–418.

    Article  CAS  PubMed  Google Scholar 

  41. Tekirian TL, Saido TC, Markesbery WR, Russell MJ, Wekstein DR, Patel E, Geddes JW (1998) N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J Neuropathol Exp Neurol 57:76–94

    Article  CAS  PubMed  Google Scholar 

  42. Wakutani Y, Watanabe K, Adachi Y, Wada-Isoe K, Urakami K, Ninomiya H, Saido TC, Hashimoto T, Iwatsubo T, Nakashima K (2004) Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease. J Neurol Neurosurg Psychiatry 75:1039–1042

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Walker LC, Diamond MI, Duff KE, Hyman BT (2013) Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurology 70:304–310.

    Article  PubMed  Google Scholar 

  44. Warner CJ, Dutta S, Foley AR, Raskatov JA (2016) Introduction of d-glutamate at a critical residue of Abeta42 stabilizes a Prefibrillary aggregate with enhanced toxicity. Chemistry 22:11967–11970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M et al (2010) Identification of low molecular weight pyroglutamate a{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem 285:41517–41524.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Zheng X, Deng L, Baker ES, Ibrahim YM, Petyuk VA, Smith RD (2017) Distinguishing d- and l-aspartic and isoaspartic acids in amyloid beta peptides with ultrahigh resolution ion mobility spectrometry. Chem Commun 53:7913–7916.

    Article  CAS  Google Scholar 

Download references


We would like to thank the different brain Banks and their managers for providing the tissue for this study. This includes: (i) the South West Brain Dementia Brain Bank (SWDBB) which is supported by BRACE (Bristol Research into Alzheimer’s and Care of the Elderly), Brains for Dementia Research and the Medical Research Council; (ii) the NHS Greater Glasgow and Clyde Trust as part of the UK Brain Archive Information Network (BRAIN UK) which is funded by the Medical Research Council and brainstrust. We acknowledge the Histochemistry Research Unit and the Biomedical Imaging Unit of the Faculty of Medicine, University of Southampton that facilitated tissue processing, staining and analysis.


This work was funded by a Marie Curie Intra European Fellowship within the 7th European Community Framework (Project No: 627152; Project Acronym: AlzProtAgeing, to Dr. Moro) and by the Alzheimer’s Research UK (grant ARUK-PG2012–8, to Prof Boche).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Author information

Authors and Affiliations



MLM, AM and DB designed the study. MLM, ASP, KG, CP performed all experiments. JARN provided assistance with the neuropathological assessments; MLM and DB analysed and interpreted the data. MLM wrote the manuscript and DB, JARN and AM reviewed the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Maria Luisa Moro or Delphine Boche.

Ethics declarations

Ethics approval and consent to participate

The study was covered by the ethical approval from the Brain banks that provided the tissue. The YC cohort was sourced from BRAIN UK (NRES Committee South Central Hampshire B, REC reference: 14/SC/0098), OC and AD cases from the South West Dementia Brain bank (NRES Committee South West Central Bristol, REC reference: 08/H0106/28 + 5). All donors have given informed consent for autopsy and use of their brain tissue for research purposes.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Additional file

Additional file 1:

Contains all supplemental information mentioned in this manuscript. Table S1. Characteristics of the old control and AD cohorts. Figure S1. Representation of the correlations between pE3-Aβ and phospho-TAU in OC and AD groups together. (DOC 203 kb)

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moro, M.L., Phillips, A.S., Gaimster, K. et al. Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease. acta neuropathol commun 6, 3 (2018).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: